123 related articles for article (PubMed ID: 8306242)
1. Preclinical studies with radiolabeled monoclonal antibodies for treatment of patients with B-cell malignancies.
Vervoordeldonk SF; Merle PA; van Leeuwen EF; von dem Borne AE; Slaper-Cortenbach IC
Cancer; 1994 Feb; 73(3 Suppl):1006-11. PubMed ID: 8306242
[TBL] [Abstract][Full Text] [Related]
2. Fc gamma receptor II (CD32) on malignant B cells influences modulation induced by anti-CD19 monoclonal antibody.
Vervoordeldonk SF; Merle PA; van Leeuwen EF; van der Schoot CE; von dem Borne AE; Slaper-Cortenbach IC
Blood; 1994 Mar; 83(6):1632-9. PubMed ID: 7510146
[TBL] [Abstract][Full Text] [Related]
3. Radioimmunotherapy in the pi-BCL1 B cell lymphoma model: efficacy depends on more than targeted irradiation alone.
Illidge T; Honeychurch J; Vandersteen A; Cragg M
Cancer Biother Radiopharm; 2000 Dec; 15(6):581-91. PubMed ID: 11190490
[TBL] [Abstract][Full Text] [Related]
4. Degradation of radioiodinated B cell monoclonal antibodies: inhibition via a FCgamma-receptor-II-mediated mechanism and by drugs.
Vervoordeldonk SF; Balkenende AY; van den Berg H; von dem Borne AE; van der Schoot CE; Van Leeuwen EF; Slaper-Cortenbach IC
Cancer Immunol Immunother; 1996 Jan; 42(1):24-30. PubMed ID: 8625363
[TBL] [Abstract][Full Text] [Related]
5. The importance of antibody-specificity in determining successful radioimmunotherapy of B-cell lymphoma.
Illidge TM; Cragg MS; McBride HM; French RR; Glennie MJ
Blood; 1999 Jul; 94(1):233-43. PubMed ID: 10381518
[TBL] [Abstract][Full Text] [Related]
6. Therapy with unlabeled and 131I-labeled pan-B-cell monoclonal antibodies in nude mice bearing Raji Burkitt's lymphoma xenografts.
Buchsbaum DJ; Wahl RL; Normolle DP; Kaminski MS
Cancer Res; 1992 Dec; 52(23):6476-81. PubMed ID: 1423295
[TBL] [Abstract][Full Text] [Related]
7. Enhanced antitumor effects of CD20 over CD19 monoclonal antibodies in a nude mouse xenograft model.
Hooijberg E; van den Berk PC; Sein JJ; Wijdenes J; Hart AA; de Boer RW; Melief CJ; Hekman A
Cancer Res; 1995 Feb; 55(4):840-6. PubMed ID: 7531616
[TBL] [Abstract][Full Text] [Related]
8. Effect of isotype on internalization and cytotoxicity of CD19-ricin A immunotoxins.
van Oosterhout YV; van den Herik-Oudijk IE; Wessels HM; de Witte T; van de Winkel JG; Preijers FW
Cancer Res; 1994 Jul; 54(13):3527-32. PubMed ID: 7516821
[TBL] [Abstract][Full Text] [Related]
9. Endocytosis and degradation of monoclonal antibodies targeting human B-cell malignancies.
Press OW; Farr AG; Borroz KI; Anderson SK; Martin PJ
Cancer Res; 1989 Sep; 49(17):4906-12. PubMed ID: 2667754
[TBL] [Abstract][Full Text] [Related]
10. Radioimmunotherapy for model B cell malignancies using 90Y-labeled anti-CD19 and anti-CD20 monoclonal antibodies.
Ma D; McDevitt MR; Barendswaard E; Lai L; Curcio MJ; Pellegrini V; Brechbiel MW; Scheinberg DA
Leukemia; 2002 Jan; 16(1):60-6. PubMed ID: 11840264
[TBL] [Abstract][Full Text] [Related]
11. Potentiation by interleukin 2 of Burkitt's lymphoma therapy with anti-pan B (anti-CD19) monoclonal antibodies in a mouse xenotransplantation model.
Vuist WM; v Buitenen F; de Rie MA; Hekman A; Rümke P; Melief CJ
Cancer Res; 1989 Jul; 49(14):3783-8. PubMed ID: 2472198
[TBL] [Abstract][Full Text] [Related]
12. Detailed studies on expression and function of CD19 surface determinant by using B43 monoclonal antibody and the clinical potential of anti-CD19 immunotoxins.
Uckun FM; Jaszcz W; Ambrus JL; Fauci AS; Gajl-Peczalska K; Song CW; Wick MR; Myers DE; Waddick K; Ledbetter JA
Blood; 1988 Jan; 71(1):13-29. PubMed ID: 3257143
[TBL] [Abstract][Full Text] [Related]
13. Radioimmunotherapy of B-cell lymphoma with [131I]anti-B1 (anti-CD20) antibody.
Kaminski MS; Zasadny KR; Francis IR; Milik AW; Ross CW; Moon SD; Crawford SM; Burgess JM; Petry NA; Butchko GM
N Engl J Med; 1993 Aug; 329(7):459-65. PubMed ID: 7687326
[TBL] [Abstract][Full Text] [Related]
14. Treatment of refractory non-Hodgkin's lymphoma with radiolabeled MB-1 (anti-CD37) antibody.
Press OW; Eary JF; Badger CC; Martin PJ; Appelbaum FR; Levy R; Miller R; Brown S; Nelp WB; Krohn KA
J Clin Oncol; 1989 Aug; 7(8):1027-38. PubMed ID: 2666588
[TBL] [Abstract][Full Text] [Related]
15. Low- versus high-dose radioimmunotherapy with humanized anti-CD22 or chimeric anti-CD20 antibodies in a broad spectrum of B cell-associated malignancies.
Behr TM; Wörmann B; Gramatzki M; Riggert J; Gratz S; Béhé M; Griesinger F; Sharkey RM; Kolb HJ; Hiddemann W; Goldenberg DM; Becker W
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3304s-3314s. PubMed ID: 10541379
[TBL] [Abstract][Full Text] [Related]
16. Prevention of lethal graft-versus-host disease in mice by monoclonal antibodies directed to T cells or their subsets. II. Differential effectiveness of IgG2a and IgG2b isotypes of anti-CD3 and anti-CD4 moAb.
Knulst AC; Noort WA; Tibbe GJ; Benner R; Savelkoul HF
Bone Marrow Transplant; 1994 Oct; 14(4):535-43. PubMed ID: 7858528
[TBL] [Abstract][Full Text] [Related]
17. The biologic window for chimeric L6 radioimmunotherapy.
DeNardo SJ; Mirick GR; Kroger LA; O'Grady LF; Erickson KL; Yuan A; Lamborn KR; Hellstrom I; Hellstrom KE; DeNardo GL
Cancer; 1994 Feb; 73(3 Suppl):1023-32. PubMed ID: 8306244
[TBL] [Abstract][Full Text] [Related]
18. Radiobiology of radioimmunotherapy: targeting CD20 B-cell antigen in non-Hodgkin's lymphoma.
Hernandez MC; Knox SJ
Int J Radiat Oncol Biol Phys; 2004 Aug; 59(5):1274-87. PubMed ID: 15275710
[TBL] [Abstract][Full Text] [Related]
19. Importance of antibody isotype in monoclonal anti-idiotype therapy of a murine B cell lymphoma. A study of hybridoma class switch variants.
Kaminski MS; Kitamura K; Maloney DG; Campbell MJ; Levy R
J Immunol; 1986 Feb; 136(3):1123-30. PubMed ID: 3484499
[TBL] [Abstract][Full Text] [Related]
20. Comparative binding and preclinical localization and therapy studies with radiolabeled human chimeric and murine 17-1A monoclonal antibodies.
Buchsbaum DJ; Brubaker PG; Hanna DE; Glatfelter AA; Terry VH; Guilbault DM; Steplewski Z
Cancer Res; 1990 Feb; 50(3 Suppl):993s-999s. PubMed ID: 2297753
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]